^
    10d
    Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: May 2027 --> Nov 2027 | Trial primary completion date: May 2027 --> Nov 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    Libtayo (cemiplimab-rwlc) • CDX-1140
    14d
    APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=34, Terminated, M.D. Anderson Cancer Center | Active, not recruiting --> Terminated; <75% participant accrual
    Trial termination
    |
    Keytruda (pembrolizumab) • sotigalimab (PYX-107)
    16d
    Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Providence Health & Services | Trial primary completion date: Aug 2025 --> Dec 2025
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • CDX-1140
    18d
    A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors (clinicaltrials.gov)
    P1/2, N=100, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    gemcitabine • paclitaxel • AiRuiLi (adebrelimab) • SHR-7367
    1m
    A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, Yale University | Trial completion date: Feb 2026 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • sotigalimab (PYX-107)
    1m
    REVOLUTION: Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=45, Completed, Cancer Insight, LLC | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Jul 2025
    Trial completion • Trial completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • albumin-bound paclitaxel • hydroxychloroquine • NG-350A
    1m
    A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=13, Terminated, Genmab | N=88 --> 13 | Active, not recruiting --> Terminated; After reviewing all available data from Part 1 of the trial, the Sponsor has decided not to proceed to Part 2 (randomized Phase 2) of the trial due to lack of efficacy
    Enrollment change • Trial termination
    |
    Keytruda (pembrolizumab) • tecaginlimab (GEN1042)
    2ms
    TITER: M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=77, Recruiting, EMD Serono Research & Development Institute, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    Keytruda (pembrolizumab) • irinotecan
    2ms
    GCT1042-01: GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=350, Active, not recruiting, Genmab | N=1287 --> 350 | Trial completion date: Aug 2026 --> Nov 2026
    Enrollment change • Trial completion date • First-in-human
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • tecaginlimab (GEN1042)
    2ms
    OPTIMIZE-1: Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients (clinicaltrials.gov)
    P1/2, N=94, Active, not recruiting, Alligator Bioscience AB | Trial primary completion date: Jan 2024 --> Jun 2026
    Trial primary completion date
    |
    5-fluorouracil • irinotecan • mitazalimab (ADC-1013)
    2ms
    INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, University of Texas Southwestern Medical Center | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    oxaliplatin • sotigalimab (PYX-107)
    2ms
    IGNITE: Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, University of Pennsylvania
    New P2 trial
    |
    Imprime PGG (odetiglucan) • mitazalimab (ADC-1013)